Abstract | BACKGROUND: METHODS:
GERD patients with dyspepsia were enrolled and treated with lansoprazole 15 or 30 mg once daily for 4 weeks. Reflux and dyspeptic symptoms were assessed by questionnaires before treatment, and 2 and 4 weeks after the start of lansoprazole treatment. RESULTS: In the effectiveness analysis set (n = 12,653), heartburn was reported by 91.6 % of patients at study enrollment. Postprandial fullness was the most frequently reported dyspepsia symptom at the start of the study, reported by 79.0 % of enrolled patients. After 4 weeks of lansoprazole treatment, heartburn symptoms were improved in 75.7 % of patients and symptoms of postprandial fullness were improved in 68.7 % of patients. The therapeutic effect of low and high doses of lansoprazole on dyspepsia, as well as on reflux symptoms, was approximately 10 % higher in patients with endoscopy-confirmed erosive esophagitis (60.1-82.2 %), than in patients with non-erosive reflux diseases (53.0-73.3 %). Lansoprazole was well tolerated. CONCLUSION: In this large-scale clinical study, lansoprazole effectively relieved dyspepsia in addition to reflux symptoms in patients with GERD.
|
Authors | Yoshikazu Kinoshita, Hiroto Miwa, Katsuyuki Sanada, Koji Miyata, Ken Haruma |
Journal | Journal of gastroenterology
(J Gastroenterol)
Vol. 49
Issue 4
Pg. 628-37
(Apr 2014)
ISSN: 1435-5922 [Electronic] Japan |
PMID | 23653056
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Proton Pump Inhibitors
- Lansoprazole
|
Topics |
- Adult
- Aged
- Dyspepsia
(complications, drug therapy)
- Esophagitis, Peptic
(drug therapy, etiology)
- Female
- Gastroesophageal Reflux
(complications, drug therapy)
- Heartburn
(drug therapy, etiology)
- Humans
- Japan
- Lansoprazole
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Prospective Studies
- Proton Pump Inhibitors
(administration & dosage, therapeutic use)
|